These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 22161505)

  • 1. A dynamic model for the risk of bladder cancer progression.
    Porta N; Calle ML; Malats N; Gómez G
    Stat Med; 2012 Feb; 31(3):287-300. PubMed ID: 22161505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
    Novara G; De Marco V; Gottardo F; Dalpiaz O; Bouygues V; Galfano A; Martignoni G; Patard JJ; Artibani W; Ficarra V
    Cancer; 2007 Oct; 110(8):1715-22. PubMed ID: 17724728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study.
    Dyrskjøt L; Zieger K; Real FX; Malats N; Carrato A; Hurst C; Kotwal S; Knowles M; Malmström PU; de la Torre M; Wester K; Allory Y; Vordos D; Caillault A; Radvanyi F; Hein AM; Jensen JL; Jensen KM; Marcussen N; Orntoft TF
    Clin Cancer Res; 2007 Jun; 13(12):3545-51. PubMed ID: 17575217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
    Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
    J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Artificial intelligence and bladder cancer arrays.
    Wild PJ; Catto JW; Abbod MF; Linkens DA; Herr A; Pilarsky C; Wissmann C; Stoehr R; Denzinger S; Knuechel R; Hamdy FC; Hartmann A
    Verh Dtsch Ges Pathol; 2007; 91():308-19. PubMed ID: 18314629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.
    Ather MH; Zaidi M
    Urol J; 2009; 6(3):189-93. PubMed ID: 19711273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of patients with carcinoma in situ of the urinary bladder.
    Cheng L; Cheville JC; Neumann RM; Leibovich BC; Egan KS; Spotts BE; Bostwick DG
    Cancer; 1999 Jun; 85(11):2469-74. PubMed ID: 10357420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
    Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
    Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of tumor recurrence: a strong predictor of stage progression in initially diagnosed nonmuscle invasive bladder cancer.
    Tanaka N; Kikuchi E; Matsumoto K; Miyajima A; Nakagawa K; Oya M
    J Urol; 2011 Feb; 185(2):450-5. PubMed ID: 21167533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A complex approach to prediction of long-term results of urinary bladder cancer treatment].
    Zimichev AA; Prianichnikova MB; Maklakov VN
    Urologiia; 2010; (3):47-9. PubMed ID: 20734878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
    Denzinger S; Otto W; Fritsche HM; Roessler W; Wieland WF; Hartmann A; Burger M
    Int J Urol; 2007 Nov; 14(11):995-9; discussion 999. PubMed ID: 17956523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk profiles of three clinical types of carcinoma in situ of the bladder.
    Meijer RP; van Onna IE; Kok ET; Bosch R
    BJU Int; 2011 Sep; 108(6):839-43. PubMed ID: 21166747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder.
    Nuhn P; May M; Sun M; Fritsche HM; Brookman-May S; Buchner A; Bolenz C; Moritz R; Herrmann E; Burger M; Tilki D; Trojan L; Perrotte P; Haferkamp A; Hohenfellner M; Wieland WF; Müller SC; Karakiewicz PI; Bastian PJ
    Eur Urol; 2012 Jan; 61(1):58-64. PubMed ID: 21840642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of muscle-invasive bladder cancer in Victoria, 1990-1995.
    Millar JL; Frydenberg M; Toner G; Syme R; Thursfield V; Giles GG;
    ANZ J Surg; 2006 Mar; 76(3):113-9. PubMed ID: 16626343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.